Developing therapies for type 1 diabetes

Diamyd® and Remygen® are drugs in clinical development phase,
aimed to preserve and restore the body's insulin production.

 

The Phase 3 trial is based on the notion of precision medicine, where only individuals that we know beforehand to have a high likelihood of benefitting from the treatment will be enrolled.

Ulf Hannelius
President and CEO, Diamyd Medical AB

ABOUT DIAMYD MEDICAL

Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development.

We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®.

Diamyd® and Remygen® are evaluated in ongoing clinical studies. The therapies target the underlying causes of diabetes, dysfunction and loss of the pancreas's insulin-producing cells.

Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.

 

ORGANISATION

Internal core competences constitute Diamyd Medical's core employees in collaboration with a global network of clinics, researchers and production units. Further expertise, including analysis- and laboratory services are contracted as needed during specific project phases. The model is based on long-term collaborations and cost efficiency.

Order GAD for preclinical research

GAD PRODUCTS